News | January 28, 2023
Aarti Drugs Q3 FY23 revenue grows 4%
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project
Subscribe To Our Newsletter & Stay Updated
